美国 · SEC FORM 4
Latigo Biotherapeutics, Inc.
LTGO · Nasdaq · CIK 0002056611 · Healthcare · Biotechnology
内部人信号
2 位买方 · 2 条买入交易行 · $5.0M 买入总额
为什么有这个信号？
评分构成
每条进度条表示其对当前分数的贡献；权重和公式保持不变。
哪些因素限制了当前分数？
- ⚠ Cluster breadth is moderate · 2 insider(s), not 4+
- ⚠ 角色得分低 · 买入者中职位最高的是：TenPercentOwner（CEO、董事长和持股 10% 以上的股东得分最低）
- ⚠ Purchase activity is becoming less recent
Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.
US-v1.2 按当前 180 天规则给合资格的股票买入打分。分数只表示研究的先后，不是收益预测或概率。回测没有显示美国分数越高、之后的表现越好。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
买方广度与集中度
Roles in the peak window: Director,TenPercentOwner, TenPercentOwner. Concentration uses priced qualifying P lines only and does not change the saved score.
信号历史
最新留档分数
- 63.3
- 63.3
- 63.3
- 63.1
- 63.0
Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
市场背景补充近期价格表现与风险信息，不影响内部人信号。
价格表现
- 1M
- -25.7%
- 3M
- —
- 6M
- —
- 12M
- —
波动率与流动性
- 波动率
- 70.0%
- Beta
- —
- 平均每日成交额
- USD 6.2M
估值
- 市值
- USD 1.1B
- P/E
- —
基本面
- 利润率
- —
- ROE
- —
- 细分行业
- Biotechnology
市场数据
价格数据截至：2026-10-11 · 价格来源：OpenBB/yfinance; 成交量来自 本机价格缓存 (yfinance) · 来自 SEC 申报文件：市值 · 市值 = 申报文件封面所列的已发行股数 × 最新收盘价。股数日期：2026-09-01 · Status: PASS
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 832,088
- 上期报告
- 449,962
- 日均成交量
- 519,457
- 回补天数
- 1.6
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-10 | Tananbaum James B. | 买入 (P) | Common Stock | 140,000 | USD 18.00 | USD 2,520,000 | SEC 申报 ↗ |
| 2026-08-10 | Foresite Capital Fund V, L.P.; Foresite Capital Fund VI LP; Foresite Capital Management V, LLC; Foresite Capital Management VI LLC; Foresite Capital Opportunity Fund V, L.P.; Foresite Capital Opportunity Management V, LLC | 买入 (P) | Common Stock | 140,000 | USD 18.00 | USD 2,520,000 | SEC 申报 ↗ |
Form 4 申报证据
32 transaction lines in the latest 365-day window; 32 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-10 | Sanofi | C (C) | Common Stock | 672,778 | USD — | USD — | SEC 申报 ↗ |
| 2026-08-10 | 5AM Opportunities II (GP), LLC; 5AM Opportunities II, L.P.; 5AM Partners VI, LLC; 5AM Ventures VI, L.P.; PARMAR KUSH; Schwab Andrew J. | C (C) | Common Stock | 7,325,962 | USD — | USD — | SEC 申报 ↗ |
| 2026-08-10 | Westlake BioPartners Fund I, L.P.; Westlake BioPartners Fund II, L.P.; Westlake BioPartners GP I, LLC; Westlake BioPartners GP II, LLC; Westlake BioPartners Opportunity Fund I, L.P.; Westlake BioPartners Opportunity GP I, LLC | C (C) | Common Stock | 12,695,305 | USD — | USD — | SEC 申报 ↗ |
展开近期 Form 4 证据 (8 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-10 | Sanofi | C (C) | Common Stock | 672,778 | USD — | USD — | SEC 申报 ↗ |
| 2026-08-10 | 5AM Opportunities II (GP), LLC; 5AM Opportunities II, L.P.; 5AM Partners VI, LLC; 5AM Ventures VI, L.P.; PARMAR KUSH; Schwab Andrew J. | C (C) | Common Stock | 7,325,962 | USD — | USD — | SEC 申报 ↗ |
| 2026-08-10 | Westlake BioPartners Fund I, L.P.; Westlake BioPartners Fund II, L.P.; Westlake BioPartners GP I, LLC; Westlake BioPartners GP II, LLC; Westlake BioPartners Opportunity Fund I, L.P.; Westlake BioPartners Opportunity GP I, LLC | C (C) | Common Stock | 12,695,305 | USD — | USD — | SEC 申报 ↗ |
| 2026-08-10 | Tananbaum James B. | 买入 (P) | Common Stock | 140,000 | USD 18.00 | USD 2,520,000 | SEC 申报 ↗ |
| 2026-08-10 | Tananbaum James B. | C (C) | Common Stock | 5,923,664 | USD — | USD — | SEC 申报 ↗ |
| 2026-08-10 | SEIDENBERG BETH C | C (C) | Common Stock | 12,695,305 | USD — | USD — | SEC 申报 ↗ |
| 2026-08-10 | Foresite Capital Fund V, L.P.; Foresite Capital Fund VI LP; Foresite Capital Management V, LLC; Foresite Capital Management VI LLC; Foresite Capital Opportunity Fund V, L.P.; Foresite Capital Opportunity Management V, LLC | 买入 (P) | Common Stock | 140,000 | USD 18.00 | USD 2,520,000 | SEC 申报 ↗ |
| 2026-08-10 | Foresite Capital Fund V, L.P.; Foresite Capital Fund VI LP; Foresite Capital Management V, LLC; Foresite Capital Management VI LLC; Foresite Capital Opportunity Fund V, L.P.; Foresite Capital Opportunity Management V, LLC | C (C) | Common Stock | 5,923,664 | USD — | USD — | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | LTGO |
| CIK | 0002056611 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 32 transaction lines from 2026-08-10 to 2026-08-10 2 P purchase lines · 0 S sale lines · 30 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.